nach oben

Die Gynäkologie

Erschienen in:

08.03.2022 | Brachytherapie | CME

Aktuelle Diagnostik und Therapie des Endometriumkarzinoms

verfasst von: Dr. med. Davut Dayan, Prof. Dr. Wolfgang Janni, Kerstin Pfister

Erschienen in: Die Gynäkologie | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Endometriumkarzinom („endometrial carcinoma“, EC) ist die vierthäufigste Krebserkrankung der Frau in Deutschland. Mit Zunahme der Risikofaktoren (allen voran Adipositas) nimmt die Inzidenz zu. Aufgrund der Initialsymptome der Blutungsstörung in der Prämenopause bzw. postmenopausale Blutung wird das EC überwiegend im Frühstadium durch Hysteroskopie mit fraktionierter Abrasio diagnostiziert. Pathologisch lässt sich das EC in Typ‑I (östrogenabhängiges endometrioides Adenokarzinom mit guter Prognose) und Typ-II (östrogenunabhängiges seröses, klarzelliges Karzinom mit schlechterer Prognose) unterteilen. Die minimal-invasive Behandlung mittels laparoskopischer totaler Hysterektomie mit Adnexektomie beidseits stellt den Goldstandard der Behandlung des frühen endometrioiden Adenokarzinoms dar. Im fortgeschrittenen Stadium, hingegen, sowie bei Typ-II-Karzinomen sind zusätzlich eine paraaortale und pelvine Lymphonodektomie bzw. eine Omentektomie notwendig. Neue wissenschaftliche Errungenschaften zu molekularbiologischen Typisierungen des EC stellen uns vor Herausforderungen in der routinemäßigen Patientinnenversorgung. Während POLE(„polymerase epsilon“)-mutierte Tumoren eine sehr gute Prognose haben, zeigen die MSI(„microsatellite instability“)-„hypermutated“ und „copy number low“ (auch „no specific molecular risk profile“, NSMP) Tumoren eine intermediäre Prognose, die „copy number high“ (auch TP53[„tumor protein 53“]-mutiert) die schlechteste. L1CAM(„L1 neuronal cell adhesion molecule“)-Positivität ist ein weiterer ungünstiger Prognosefaktor.

Robert Koch-Institut, Gesellschaft der Epidemiologischen Krebsregister in Deutschland E. V. (2019) Krebs in Deutschland für 2015/2016. Robert Koch-Institut, Gesellschaft der Epidemiologischen Krebsregister in Deutschland E. V., Berlin

Beral V, Bull D, Reeves G et al (2005) Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365:1543–1551PubMed

Demichele A, Troxel AB, Berlin JA et al (2008) Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. J Clin Oncol 26:4151–4159PubMedPubMedCentral

Raglan O, Kalliala I, Markozannes G et al (2019) Risk factors for endometrial cancer: an umbrella review of the literature. Int J Cancer 145:1719–1730PubMed

Egoavil C, Alenda C, Castillejo A et al (2013) Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers. Plos One 8:e79737PubMedPubMedCentral

Lu KH, Schorge JO, Rodabaugh KJ et al (2007) Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol 25:5158–5164PubMed

Deutsche Krebsgesellschaft, Deutsche Krebshilfe, Awmf (2018) Leitlinienprogramm Onkologie: Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom, Langversion1.0, AWMF Registernummer: 032/034-OL

Church JM (2014) Polymerase proofreading-associated polyposis: a new, dominantly inherited syndrome of hereditary colorectal cancer predisposition. Dis Colon Rectum 57:396–397PubMed

Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261–268PubMed

10.

Kurman R, Carcangiu M, Herrington CS, Young R (2014) World Health Organisation classification of tumours of the female reproductive organs, 4. Aufl. International Agency for Research on Cancer (IARC) Press, Lyon

11.

Zaino RCS, Ellenson LH et al (2014) Tumours of the uterine corpus: epithelial tumours and precursors. In: Kurman RJ, Carcanglu ML, Herrington CS, Young RH (Hrsg) WHO Classification of Tumours of female reproductive Organs

12.

Antonsen SL, Ulrich L, Hogdall C (2012) Patients with atypical hyperplasia of the endometrium should be treated in oncological centers. Gynecol Oncol 125:124–128PubMed

13.

Owings RA, Quick CM (2014) Endometrial intraepithelial neoplasia. Arch Pathol Lab Med 138:484–491PubMed

14.

Lacey JV Jr., Sherman ME, Rush BB et al (2010) Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol 28:788–792PubMedPubMedCentral

15.

Emons G, Beckmann MW, Schmidt D et al (2015) New WHO classification of Endometrial Hyperplasias. Geburtshilfe Frauenheilkd 75:135–136PubMedPubMedCentral

16.

Gallos ID, Ofinran O, Shehmar M et al (2011) Current management of endometrial hyperplasia—a survey of United Kingdom consultant gynaecologists. Eur J Obstet Gynecol Reprod Biol 158:305–307PubMed

17.

Gallos ID, Yap J, Rajkhowa M et al (2012) Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 207:266e1–266e12

18.

Simpson AN, Feigenberg T, Clarke BA et al (2014) Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin. Gynecol Oncol 133:229–233PubMed

19.

Trimble CL, Method M, Leitao M et al (2012) Management of endometrial precancers. Obstet Gynecol 120:1160–1175PubMedPubMedCentral

20.

Pennant ME, Mehta R, Moody P et al (2017) Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG 124:404–411PubMed

21.

Clarke MA, Long BJ, Del Mar Morillo A et al (2018) Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis. JAMA Intern Med 178:1210–1222PubMedPubMedCentral

22.

Gerber B, Krause A, Muller H et al (2001) Ultrasonographic detection of asymptomatic endometrial cancer in postmenopausal patients offers no prognostic advantage over symptomatic disease discovered by uterine bleeding. Eur J Cancer 37:64–71PubMed

23.

Anonymous (2018) ACOG committee opinion no. 734: the role of Transvaginal ultrasonography in evaluating the endometrium of women with postmenopausal bleeding. Obstet Gynecol 131:e124–e129

24.

Timmermans A, Opmeer BC, Khan KS et al (2010) Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol 116:160–167PubMed

25.

Clarke MA et al (2020) Risk assessment of endometrial cancer and endometrial intraepithelial neoplasia in women with abnormal bleeding and implications for clinical management algorithms. Am J Obstet Gynecol. https://doi.org/10.1016/j.ajog.2020.03.032CrossRefPubMedPubMedCentral

26.

El-Sharkawy M, El-Mazny A, Ramadan W et al (2016) Three-dimensional ultrasonography and power Doppler for discrimination between benign and malignant endometrium in premenopausal women with abnormal uterine bleeding. BMC Womens Health 16:18. https://doi.org/10.1186/s12905-016-0297-3CrossRefPubMedPubMedCentral

27.

Wise MR, Gill P, Lensen S et al (2016) Body mass index trumps age in decision for endometrial biopsy: cohort study of symptomatic premenopausal women. Am J Obstet Gynecol 215:598e1–598e8

28.

Esposito K et al (2014) Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine. https://doi.org/10.1007/s12020-013-9973-3CrossRefPubMed

29.

Aune D et al (2015) Anthropometric factors and endometrial cancer risk: a systematic review and dose–response meta-analysis of prospective studies. Ann Oncol. https://doi.org/10.1093/annonc/mdv142CrossRefPubMed

30.

Crosbie EJ et al (2010) Body Mass Index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Canc Epidem Biomark Prev. https://doi.org/10.1158/1055-9965.EPI-10-0832CrossRef

31.

Abdelazim IA, Abdelrazak KM, Elbiaa AA et al (2015) Accuracy of endometrial sampling compared to conventional dilatation and curettage in women with abnormal uterine bleeding. Arch Gynecol Obstet 291:1121–1126PubMed

32.

Brierley J, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours. John Wiley & Sons, Chichester Hoboken

33.

Weiderpass E, Antoine J, Bray FI et al (2014) Trends in corpus uteri cancer mortality in member states of the European Union. Eur J Cancer 50:1675–1684PubMed

34.

Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15:10–17PubMed

35.

Matias-Guiu X, Catasus L, Bussaglia E et al (2001) Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 32:569–577PubMed

36.

Kuhn E, Wu RC, Guan B et al (2012) Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst 104:1503–1513PubMedPubMedCentral

37.

Cancer Genome Atlas Research N, Research N, Kandoth C, Schultz N et al (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497:67–73

38.

Talhouk A, Mcconechy MK, Leung S et al (2017) Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 123:802–813PubMed

39.

Reijnen C, Kusters-Vandevelde HVN, Prinsen CF et al (2019) Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. Gynecol Oncol 154:124–130PubMed

40.

Kommoss FK, Karnezis AN, Kommoss F et al (2018) L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer 119:480–486PubMedPubMedCentral

41.

Schultheis AM, Martelotto LG, De Filippo MR et al (2016) TP53 mutational spectrum in endometrioid and serous endometrial cancers. Int J Gynecol Pathol 35:289–300PubMedPubMedCentral

42.

Leon-Castillo A, De Boer SM, Powell ME et al (2020) Molecular classification of the PORTEC‑3 trial for high-risk Endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 38:3388–3397PubMedPubMedCentral

43.

Zeimet AG, Reimer D, Huszar M et al (2013) L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst 105:1142–1150PubMed

44.

Buza N, English DP, Santin AD et al (2013) Toward standard HER2 testing of endometrial serous carcinoma: 4‑year experience at a large academic center and recommendations for clinical practice. Mod Pathol 26:1605–1612PubMed

45.

Galaal K, Bryant A, Fisher AD et al (2012) Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006655.pub2CrossRefPubMed

46.

Walker JL, Piedmonte MR, Spirtos NM et al (2012) Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol 30:695–700PubMedPubMedCentral

47.

Walker JL, Piedmonte MR, Spirtos NM et al (2009) Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol 27:5331–5336PubMedPubMedCentral

48.

Zullo F, Falbo A, Palomba S (2012) Safety of laparoscopy vs laparotomy in the surgical staging of endometrial cancer: a systematic review and metaanalysis of randomized controlled trials. Am J Obstet Gynecol 207:94–100PubMed

49.

Chan JK, Gardner AB, Taylor K et al (2015) Robotic versus laparoscopic versus open surgery in morbidly obese endometrial cancer patients—a comparative analysis of total charges and complication rates. Gynecol Oncol 139:300–305PubMed

50.

Walsh C, Holschneider C, Hoang Y et al (2005) Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol 106:693–699PubMed

51.

Takano M, Ochi H, Takei Y et al (2013) Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)? Br J Cancer 109:1760–1765PubMedPubMedCentral

52.

Favero G, Anton C, Le X et al (2016) Oncologic safety of laparoscopy in the surgical treatment of type II endometrial cancer. Int J Gynecol Cancer 26:1673–1678PubMed

53.

Mariani A, Dowdy SC, Cliby WA et al (2008) Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 109:11–18PubMedPubMedCentral

54.

Carlson JW, Kauderer J, Hutson A et al (2020) GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients. Gynecol Oncol 156:467–474PubMed

55.

Persson J, Salehi S, Bollino M et al (2019) Pelvic Sentinel lymph node detection in High-Risk Endometrial Cancer (SHREC-trial)-the final step towards a paradigm shift in surgical staging. Eur J Cancer 116:77–85PubMed

56.

Holloway RW, Abu-Rustum NR, Backes FJ et al (2017) Sentinel lymph node mapping and staging in endometrial cancer: a Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol 146:405–415PubMedPubMedCentral

57.

Jewell EL, Huang JJ, Abu-Rustum NR et al (2014) Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies. Gynecol Oncol 133:274–277PubMedPubMedCentral

58.

Perrone AM, Casadio P, Formelli G et al (2008) Cervical and hysteroscopic injection for identification of sentinel lymph node in endometrial cancer. Gynecol Oncol 111:62–67PubMed

59.

Niikura H, Kaiho-Sakuma M, Tokunaga H et al (2013) Tracer injection sites and combinations for sentinel lymph node detection in patients with endometrial cancer. Gynecol Oncol 131:299–303PubMed

60.

Holub Z, Jabor A, Kliment L (2002) Comparison of two procedures for sentinel lymph node detection in patients with endometrial cancer: a pilot study. Eur J Gynaecol Oncol 23:53–57PubMed

61.

Abu-Rustum NR, Khoury-Collado F, Pandit-Taskar N et al (2009) Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma? Gynecol Oncol 113:163–169PubMedPubMedCentral

62.

Rossi EC, Jackson A, Ivanova A et al (2013) Detection of sentinel nodes for endometrial cancer with robotic assisted fluorescence imaging: cervical versus hysteroscopic injection. Int J Gynecol Cancer 23:1704–1711PubMed

63.

Papadia Andrea MMD (2018) Sentinel-Lymphknotenmapping mit NIR/ICG-Fluoreszensbildgebung bei Malignen Tumoren in der Gynäkologie. Endo Press,

64.

Rossi EC, Ivanova A, Boggess JF (2012) Robotically assisted fluorescence-guided lymph node mapping with ICG for gynecologic malignancies: a feasibility study. Gynecol Oncol 124:78–82PubMed

65.

Khoury-Collado F, Glaser GE, Zivanovic O et al (2009) Improving sentinel lymph node detection rates in endometrial cancer: how many cases are needed? Gynecol Oncol 115:453–455PubMed

66.

Ballester M, Dubernard G, Lecuru F et al (2011) Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol 12:469–476PubMed

67.

Holloway RW, Gupta S, Stavitzski NM et al (2016) Sentinel lymph node mapping with staging lymphadenectomy for patients with endometrial cancer increases the detection of metastasis. Gynecol Oncol 141:206–210PubMed

68.

Kim CH, Soslow RA, Park KJ et al (2013) Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. Int J Gynecol Cancer 23:964–970PubMedPubMedCentral

69.

Raimond E, Ballester M, Hudry D et al (2014) Impact of sentinel lymph node biopsy on the therapeutic management of early-stage endometrial cancer: Results of a retrospective multicenter study. Gynecol Oncol 133:506–511PubMed

70.

Basaran D, Bruce S, Aviki EM et al (2020) Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma. Gynecol Oncol 156:70–76PubMed

71.

Ducie JA, Eriksson AGZ, Ali N et al (2017) Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease. Gynecol Oncol 147:541–548PubMed

72.

Ignatov A, Papathemelis T, Ivros S et al (2020) Comparison of survival of patients with endometrial cancer undergoing sentinel node biopsy alone or systematic lymphadenectomy. Arch Gynecol Obstet 302:995–1000PubMed

73.

Kogan L, Matanes E, Wissing M et al (2020) The added value of sentinel node mapping in endometrial cancer. Gynecol Oncol 158:84–91PubMed

74.

Rossi EC, Kowalski LD, Scalici J et al (2017) A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol 18:384–392PubMed

75.

Shih KK, Yun E, Gardner GJ et al (2011) Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. Gynecol Oncol 122:608–611PubMed

76.

De Boer SM, Powell ME, Mileshkin L et al (2018) Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 19:295–309PubMedPubMedCentral

77.

Creutzberg CL, Nout RA, Lybeert ML et al (2011) Fifteen-year radiotherapy outcomes of the randomized PORTEC‑1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 81:e631–e638PubMed

78.

Nout RA, Smit VT, Putter H et al (2010) Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 375:816–823PubMed

79.

Nout RA, Putter H, Jurgenliemk-Schulz IM et al (2009) Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC‑2 trial. J Clin Oncol 27:3547–3556PubMed

80.

Wortman BG, Creutzberg CL, Putter H et al (2018) Ten-year results of the PORTEC‑2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer 119:1067–1074PubMedPubMedCentral

81.

Imboden S, Nastic D, Ghaderi M et al (2019) Phenotype of POLE-mutated endometrial cancer. PLoS ONE 14:e214318PubMedPubMedCentral

82.

Concin N, Matias-Guiu X, Vergote I et al (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 31:12–39PubMed

83.

Fader AN, Roque DM, Siegel E et al (2020) Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III–IV) or recurrent uterine serous carcinomas that overexpress her2/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res 26:3928–3935PubMedPubMedCentral

84.

Oaknin ADL, Sullivan RJ et al (2019) Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti-PD‑1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI‑H and MSS endometrial cancer. In: 2019 SGO annual meeting

85.

Makker V (2021) Virtuelles wissenschaftliches Plenum „Scientific Plenary I: Innovation and Progress in Gynecologic Oncology“. In: SGO annual meeting (Veranstalter: MSD SHARP & DOHME)

86.

Makker V, Taylor MH, Oaknin A, Herraez CA, Orlowski R, Dutta L, Ren M, Zale M, O’Malley D (2021) Characterization and management of adverse reactions in patients with advenced endometrial carzinoma treated with lenvatinib plus pembrolizumab. Oncologist 26(9):e1608. https://doi.org/10.1002/onco.1383CrossRef

87.

Ethier JL, Desautels DN, Amir E et al (2017) Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecol Oncol 147:158–166PubMed

88.

Thigpen JT, Brady MF, Alvarez RD et al (1999) Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17:1736–1744PubMed

89.

Mirza MR, Bjørge L, Marmé F et al (2020) A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptorpositive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO/ENGOT-EN3 trial. In: European Society of Medical Oncology (ESMO) Virtual Congress 2020

Titel: Aktuelle Diagnostik und Therapie des Endometriumkarzinoms
verfasst von: Dr. med. Davut Dayan
Prof. Dr. Wolfgang Janni
Kerstin Pfister
Publikationsdatum: 08.03.2022
Verlag: Springer Medizin
Schlagwörter: Brachytherapie
Endometriumkarzinom
Pflege
Endometriumkarzinom
Hysterektomie
Hysteroskopie
Östrogene
Erschienen in: Die Gynäkologie / Ausgabe 3/2022
Print ISSN: 2731-7102
Elektronische ISSN: 2731-7110
DOI: https://doi.org/10.1007/s00129-022-04909-6

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Aktuelle Diagnostik und Therapie des Endometriumkarzinoms

Zusammenfassung

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

Neue Aspekte in Diagnostik und Therapie des Endometriumkarzinoms

Kommentar zu: Neue Aspekte in Diagnostik und Therapie des Endometriumkarzinoms

Fehler oder Schicksal? Arzthaftung bei fatalem Verlauf nach Sectio

Aktuelles zur systemischen Rezidivtherapie des epithelialen Ovarialkarzinoms

Systemische Therapie und zielgerichtete Erhaltungstherapie in der Primärsituation beim high- und low-grade Ovarialkarzinom

Das Ovarialkarzinom

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie